^
    Back
    Association details:
    Biomarker:HER-2 exon 20 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions

    Excerpt:
    ...- HER2 exon 20 insertions confirmed by next generation sequencing or polymerase chain reaction (if blood samples are used, the mutation abundance should be ≥10%)....
    Trial ID:
    NCT04382300
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Med
    Title:

    Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

    Published date:
    02/01/2022
    Excerpt:
    In this multicenter, single-arm, phase II trial, stage IIIB-IV NSCLC patients harboring HER2 mutations…. Patients with exon 20 and non-exon 20 HER2 mutations had ORRs of 17.7% and 25.0%, respectively….Pyrotinib exhibited promising efficacy and acceptable safety in NSCLC patients carrying exon 20 and non-exon 20 HER2 mutations and is worth further investigation.
    DOI:
    10.1186/s12916-022-02245-z